Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Bosutinib was approved on September 4, 2012.
SynZeal offers all Bosutinib related impuritiesstandards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Bosutinib related standards are being used by major pharmaceuticalcompanies across the globe for their ANDA/DMF filing.
